Publications

484 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

GVS advice ivermectin (Stromectol®)

The National Health Care Institute advises the Minister to include ivermectin (Stromectol®) in List 1B and List 2 of the GVS. ...

Report | 20-04-2022
GVS advice avacopan (Tavneos®)

The National Health Care Institute advises the Minister not to include avacopan (Tavneos®) in the GVS. Avacopan is indicated for ...

Report | 20-04-2022
GVS advice on finerenon (Kerendia®)

The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

Report | 04-04-2022
GVS advice extension further conditions for dapagliflozin (Forxiga®)

The National Health Care Institute has completed its assessment whether the further conditions for dapagliflozin (Forxiga®) could ...

Report | 28-03-2022
GVS advice extension further conditions for elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

The National Health Care Institute has completed its assessment whether the further conditions of ...

Report | 22-03-2022
Package advice cabozantinib in combination with nivolumab (Cabometyx-Opdivo®)

The National Health Care Institute advises the Minister to include cabozantinib in combination with nivolumab (Cabometyx® in ...

Report | 14-03-2022
GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk

The National Health Care Institute advises the Minister to extend the List 2 conditions for liraglutide (Saxenda®). The ...

Report | 24-02-2022
GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...

Report | 24-02-2022
GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

Report | 22-02-2022
GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...

Report | 10-02-2022

Publications

484 publications

GVS advice ivermectin (Stromectol®)

GVS advice avacopan (Tavneos®)

GVS advice on finerenon (Kerendia®)

GVS advice extension further conditions for dapagliflozin (Forxiga®)

GVS advice extension further conditions for elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

Package advice cabozantinib in combination with nivolumab (Cabometyx-Opdivo®)

GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk

GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

Go to